DBV Technologies S.A. (NASDAQ:DBVT) Receives $35.38 Average PT from Analysts

by · The Cerbat Gem

DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, five have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $35.3750.

DBVT has been the subject of several recent analyst reports. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Guggenheim reissued a “buy” rating and issued a $51.00 target price (up previously from $35.00) on shares of DBV Technologies in a report on Wednesday. Citizens Jmp boosted their target price on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research report on Wednesday, December 17th. Finally, Zacks Research upgraded shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th.

Read Our Latest Stock Report on DBV Technologies

Insider Transactions at DBV Technologies

In other DBV Technologies news, major shareholder Bpifrance Epic sold 2,076,990 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total value of $10,073,401.50. Following the completion of the transaction, the insider directly owned 8,595,472 shares of the company’s stock, valued at approximately $41,688,039.20. This trade represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.44% of the company’s stock.

Hedge Funds Weigh In On DBV Technologies

Several hedge funds have recently bought and sold shares of the company. Nan Fung Trinity HK Ltd. purchased a new stake in DBV Technologies during the second quarter worth $340,000. Vivo Capital LLC acquired a new position in shares of DBV Technologies during the 2nd quarter worth $9,659,000. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies in the 2nd quarter worth about $9,649,000. Adage Capital Partners GP L.L.C. acquired a new stake in DBV Technologies in the 2nd quarter valued at about $9,659,000. Finally, Octagon Capital Advisors LP purchased a new position in DBV Technologies during the 2nd quarter valued at about $9,315,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Stock Up 5.8%

Shares of NASDAQ:DBVT opened at $22.76 on Friday. DBV Technologies has a 52 week low of $2.92 and a 52 week high of $26.18. The company has a 50-day moving average price of $15.38 and a 200 day moving average price of $11.88. The company has a market cap of $914.04 million, a P/E ratio of -4.40 and a beta of -1.10.

Key Stores Impacting DBV Technologies

Here are the key news stories impacting DBV Technologies this week:

  • Positive Sentiment: Phase‑III win in peanut allergy improves commercial/clinical outlook — a Bioworld report says DBV’s VIT® program delivered a positive Phase III result, a material de‑risking event for a lead program that can drive future revenue and re‑rating. Vitesse finesse pays off: DBV wins in peanut allergy phase III
  • Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts, signaling stronger long‑term profitability expectations (FY2027–FY2029 upgrades). That upward revision likely helped investor sentiment and price momentum. HC Wainwright Expects Stronger Earnings for DBV Technologies
  • Positive Sentiment: Additional bullish analyst notes and coverage changes — the stock was reported to hit a new 1‑year high after analyst upgrades, and coverage consensus sits around a “Moderate Buy,” with at least one firm (Citizens JMP) forecasting strong price appreciation. Those actions typically boost retail/institutional interest. DBV Technologies (NASDAQ:DBVT) Hits New 1-Year High Following Analyst Upgrade
  • Neutral Sentiment: Market consensus EPS remains deeply negative for the current year (consensus ~($7.05) EPS), so while upgrades are meaningful, the company is still transitioning from loss‑making to profitable — investors should watch upcoming milestones and cash runway closely.
  • Negative Sentiment: Major shareholder Bpifrance Epic sold large blocks of stock on Dec 17–18 (combined ~3.37M shares sold across two days, materially reducing its stake). Large insider/major‑holder selling can pressure the stock and signal liquidity‑driven exits even when fundamentals improve. SEC filing: Bpifrance Epic Insider Sales SEC Filing
  • Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (worse near‑term profitability view), a reminder that boutique analysts still see near‑term execution and cash burn risk — this can cap upside until revenue/profitability is proven.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

See Also